Interferons, immunity and cancer immunoediting
The DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index.
Abstract
A clear picture of the dynamic relationship between the host immune system and cancer is emerging as the cells and molecules that participate in naturally occurring antitumour immune responses are being identified. The interferons (IFNs) - that is, the type I IFNs (IFNalpha and IFNbeta) and type II IFN (IFNgamma) - have emerged as central coordinators of tumour-immune-system interactions. Indeed, the decade-old finding that IFNgamma has a pivotal role in promoting antitumour responses became the focus for a renewed interest in the largely abandoned concept of cancer immunosurveillance. More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a cytokine which promotes increased tumour immunogenicity and often used to assess T-cell activation31”
From Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis (2016) · cites this paper as [31]
Citations
Cites
1 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577 · cited 1×
“However, it remains unclear whether the tumour-suppressor functions of RNaseL depend on IFN”
BackgroundRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Using a combination of histological and gene-expression analyses, Galon et al”
MethodCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Self-citationCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×
“These pathways coordinately defend cells from the oncogenic and/or genotoxic stimuli that can lead to malignant transformatio”
BackgroundHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932 · cited 1×
“Detailed reviews of IFN biology have been published elsewher”
BackgroundSelf-citationMechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citation
Research works printed but not linked: 1
- Yang, J., Murphy, T. L., Ouyang, W. & Murphy, K. M. Induction of interferon-γ production in TH1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur. J. Immunol. 29, 548–555 (1999). · DOI · Paper page
Cited by
Items 401–500 of 1,002
Opioids and cancer: friend or foe?
Wigmore, T., & Farquhar-Smith, P. W. (2016) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000208 · Cited by 78
“es, C ing ich m s ev nd f [2] Vascular endothelial cells within tumours may not express the requisite adhesion molecules for cytotoxic lymphocytes (CTLs) and similar cell function [4].”
BackgroundRelation, T., Yi, T., Guess, A. J., La Perle, K., Otsuru, S., Hasgur, S., Dominici, M., Breuer, C., & Horwitz, E. M. (2018) · Stem Cells · doi:10.1002/stem.2801 · Cited by 72
Chen, Z., Giotti, B., Kaluzová, M., Vallcorba, M. P., Rawat, K., Price, G. A., Herting, C. J., Piñero, G., Cristea, S., Ross, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163802 · Cited by 72
Metabolic reprogramming and interventions in angiogenesis
Liu, Y., Wu, Z., Li, Y., Chen, Y., Zhao, X., Wu, M., & Xia, Y. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.001 · Cited by 74
“In addition, activated T cells can produce IFN-c (interferon-c ) to inhibit the development of tumors [93].”
Charni, S., de Bettignies, G., Rathore, M. G., Aguiló, J. I., van den Elsen, P. J., Haouzi, D., Hipskind, R. A., Enriquez, J. A., Sanchez-Beato, M., Pardo, J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001250 · Cited by 69
Lauber, K., Brix, N., Ernst, A., Hennel, R., Krombach, J., Anders, H., & Belka, C. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.047 · Cited by 75
Respa, A., Bukur, J., Ferrone, S., Pawelec, G., Zhao, Y., Wang, E., Marincola, F. M., & Seliger, B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2114 · Cited by 71
“IFN-g can directly act on tumor cells by exerting antiproliferative, proapoptotic, and antiangiogenic effects (24).”
Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation
Frey, K., Zivanovic, A., Schwager, K., & Neri, D. (2011) · Integrative Biology · doi:10.1039/c0ib00099j · Cited by 76
Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions
Battella, S., Cox, M. C., Santoni, A., & Palmieri, G. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr0415-141r · Cited by 80
Glycosylation of OVA antigen-loaded PLGA nanoparticles enhances DC-targeting for cancer vaccination
Chou, P.-Y., Lin, S., Wu, Y., Shen, C., Sheu, M., & Ho, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.002 · Cited by 70
Advances in radiotherapy and immunity in hepatocellular carcinoma
Yang, Y., Xiong, L., Li, M., Jiang, P., Wang, J., & Li, C. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04386-y · Cited by 72
“In 2006, Dr. Robert Schreiber proposed the concept of "immune editing," which describes how tumour cells evade immune responses and even "reprogram" certain immune cells to promote tumour growth [78].”
BackgroundLi, Q., Zhang, C., Xu, G., Shang, X., Nan, X., Li, Y., Liu, J., Hong, Y., Wang, Q., & Peng, G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116172 · Cited by 73
Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses
Bhattacharya, S., HuangFu, W.-C., Dong, G., Qian, J., Baker, D. P., Karar, J., Koumenis, C., Diehl, J. A., & Fuchs, S. Y. (2013) · Oncogene · doi:10.1038/onc.2012.439 · Cited by 68
Potential Targets for Pancreatic Cancer Immunotherapeutics
Dodson, L. F., Hawkins, W. G., & Goedegebuure, P. S. (2011) · Immunotherapy · doi:10.2217/imt.11.10 · Cited by 74
Stratikos, E., Stamogiannos, A., Zervoudi, E., & Fruci, D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00363 · Cited by 73
Thang, N. N. T., Derouazi, M., Philippin, G., Arcidiaco, S., Berardino-Besson, W. D., Masson, F., Hoepner, S., Riccadonna, C., Burkhardt, K., Guha, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3074 · Cited by 73
“Despite compelling data showing glioma-infiltrating immune cells and several mechanisms of immune escape (3, 32, 33), the dynamics of these local interactions were not directly explored in spontaneous glioma.”
BackgroundHLA‐G: Function, polymorphisms and pathology
Arnaiz‐Villena, A., Juárez, I., Suárez‐Trujillo, F., López‐Nares, A., Vaquero‐Yuste, C., Palacio-Grüber, J., & Martín‐Villa, J. M. (2020) · International Journal of Immunogenetics · doi:10.1111/iji.12513 · Cited by 69
“This phenomenon is mediated by the mutational processes within the tumoural cells and by the expression of immunosuppressive factors, such as soluble MICA/B, PD-L1 and HLA-G (Carosella & Horuzsko, 2007; Dunn et al., 2006; Dunn et al., 2004).”
BackgroundAlmawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 80
Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma
Urakawa, H., Nishida, Y., Nakashima, H., Shimoyama, Y., Nakamura, S., & Ishiguro, N. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-009-9290-7 · Cited by 72
“IDO is induced in tumor cells in response to inflammatory cytokines such as IFN-c from the initial host response against the tumor [10].”
BackgroundYang, X., Lian, K., Meng, T., Liu, X., Miao, J., Tan, Y., Yuan, H., & Hu, F. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b10081 · Cited by 71
Pérez-Núñez, I., Rozalén, C., Palomeque, J. Á., Sangrador, I., Dalmau, M., Comerma, L., Hernández‐Prat, A., Casadevall, D., Menéndez, S., Liu, D. D., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00339-4 · Cited by 69
Goubau, D., Romieu, R., Solis, M., Hernandez, E., Mésplède, T., Lin, R., Leaman, D. W., & Hiscott, J. B. (2009) · European Journal of Immunology · doi:10.1002/eji.200838832 · Cited by 75
Zulkipli, I. N., Rajabalaya, R., Idris, A., Sulaiman, N. A., & David, S. R. N. (2017) · Pharmaceutical Biology · doi:10.1080/13880209.2017.1288749 · Cited by 68
“Th1 cells primarily secrete IL-2 and interferon (IFN)-c, which can suppress tumour growth by promoting CD8þ cytotoxic T lymphocyte (CTL) function (Dunn et al. 2006).”
BackgroundTiffen, J. C., Gallagher, S. J., Filipp, F. V., Gunatilake, D., Emran, A. A., Cullinane, C. M., Dutton‐Regester, K., Aoude, L. G., Hayward, N. K., Chatterjee, A., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.02.042 · Cited by 75
“2448 EZH2 represses IFN signaling that can be reversed by EZH2 inhibitor treatment IFN responses are critical for antigen presentation and adaptive immune responses (Dunn et al., 2006), so we”
BackgroundHuman autoantibodies neutralizing type I IFNs: From 1981 to 2023
Bastard, P., Gervais, A., Voyer, T. L., Philippot, Q., Cobat, A., Rosain, J., Jouanguy, E., Abel, L., Zhang, S., Zhang, Q., et al. (2024) · Immunological Reviews · doi:10.1111/imr.13304 · Cited by 72
“207,208 An appealing hypothesis is that the emergence of auto-Abs against type I IFNs with age might modulate the anti-tumor effects of type I IFNs.”
BackgroundMizutani, T., Neugebauer, N., Putz, E. M., Moritz, N., Simma, O., Zebedin-Brandl, E., Gotthardt, D., Warsch, W., Eckelhart, E., Kantner, H.-P., et al. (2012) · OncoImmunology · doi:10.4161/onci.21284 · Cited by 68
“Further experiments using bone marrow chimeras led to the conclusion that the hematopoietic cells of the host need to be sensitive to Type I IFN for tumor rejection and that endogenously produced or therapeutically administered Type I IFN mediates its antitumor effects mainly through acting on host hematopoietic cells…”
Camicia, R., Bachmann, S. B., Winkler, H. C., Beer, M., Tinguely, M., Haralambieva, E., & Hassa, P. O. (2013) · Journal of Cell Science · doi:10.1242/jcs.118174 · Cited by 67
“J o u rn a l o f C e ll S c ie n c e IFNc exhibits both pro- and anti-tumor properties, depending on the context and cancer type (Dunn et al., 2006).”
BackgroundMyeloid-derived Suppressor Cells (MDSCs) in Gliomas and Glioma-Development
Kohanbash, G., & Okada, H. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.689591 · Cited by 71
“Recent studies demonstrate that hematopoietic cells in the host (rather than tumor cells) are the crucial mediators of the antitumor activity elicited by endogenous type 1 IFNs (Hervas-Stubbs et al., 2011; Dunn, Koebel, and Schreiber, 2006).”
BackgroundCheckpoint Inhibition in Myeloma: Opportunities and Challenges
Costa, F., Das, R., Bailur, J. K., Dhodapkar, K. M., & Dhodapkar, M. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02204 · Cited by 70
“, indoleamine 2,3-dioxygenase (IDO), type I interferons (IFNs) and IFN-γ, galectin-1, have been described in the disruption of immune homeostasis and in the altered balance from effector to regulatory and suppressive cells induced by cancer (7, 9).”
BackgroundRiley, C. H., Jensen, M. K., Brimnes, M. K., Hasselbalch, H. C., Bjerrum, O. W., Straten, P. T., & Svane, I. M. (2011) · Blood · doi:10.1182/blood-2011-03-340992 · Cited by 68
Huang, D., Guo, W., Gao, J., Chen, J., & Olatunji, O. J. (2015) · Molecules · doi:10.3390/molecules200917405 · Cited by 73
Liu, J., Qian, X., Chen, Z., Xu, X., Gao, F., Zhang, S., Zhang, R., Qi, J., Gao, G. F., & Yan, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200324 · Cited by 66
Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research
Overgaard, N. H., Fan, T. M., Schachtschneider, K. M., Principe, D. R., Schook, L. B., & Jungersen, G. (2018) · ILAR Journal · doi:10.1093/ilar/ily014 · Cited by 72
The roles of curcumin in regulating the tumor immunosuppressive microenvironment (Review)
Wang, Y., Lü, J., Jiang, B., & Guo, J. (2020) · Oncology Letters · doi:10.3892/ol.2020.11437 · Cited by 83
“Previous research has suggested that in the early stage of tumors, both innate and adaptive immunity are active in immune surveillance, thereby suppressing spontaneous tumorigenesis, which is usually transient (58,59).”
BackgroundTrial watch: intratumoral immunotherapy
Humeau, J., Naour, J. L., Galluzzi, L., Kroemer, G., & Pol, J. G. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1984677 · Cited by 67
Cheriyath, V., Kuhns, M. A., Jacobs, B., Evangelista, P. J., Elson, P. J., Downs-Kelly, E. P., Tubbs, R., & Borden, E. C. (2011) · Oncogene · doi:10.1038/onc.2011.393 · Cited by 68
“Interferons (IFNs) are a group of cytokines that are an integral part of immune surveillance and can eradicate malignant cells as they emerge (Dunn et al., 2006; Borden et al., 2007).”
BackgroundThe confluence of radiotherapy and immunotherapy
Burnette, B., Fu, Y., & Weichselbaum, R. R. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00143 · Cited by 68
“…of Radiation and Cellular Oncology, The Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL, USA Edited by: Sandra Demaria, New York University School of Medicine, USA Reviewed by: Elizabeth A. Repasky, Roswell Park Cancer Institute, USA Chandan Guha, Albert…”
BackgroundWen, L., Xin, B., Wu, P., Lin, C., Peng, C., Wang, G., Lee, J., Lu, L., & Feng, G. (2019) · Hepatology · doi:10.1002/hep.30528 · Cited by 65
“S9C, top), which was regarded as a sign of activated antitumor immunity.(30) A heatmap showed that the combination treatment maximized IFNγ signaling in hepatic immune cells.”
Exploring TGF-β Signaling in Cancer Progression: Prospects and Therapeutic Strategies
Sheikh, K., Amjad, M., Irfan, M., Anjum, S., Majeed, T., Riaz, M. U., Jassim, A. Y., Sharif, E., & Ibrahim, W. N. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s493643 · Cited by 69
Targeting Interferons in Systemic Lupus Erythematosus: Current and Future Prospects
Mathian, A., Hie, M., Aubart, F. C., & Amoura, Z. (2015) · Drugs · doi:10.1007/s40265-015-0394-x · Cited by 68
Qamra, A., Xing, M., Padmanabhan, N., Kwok, J. J. T., Zhang, S., Xu, C., Leong, Y. S., Lim, A. P. L., Tang, Q., Ooi, W. F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1022 · Cited by 68
Sanders, K. L., Fox, B. A., & Bzik, D. J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0235 · Cited by 64
“IFNg production is required for the therapeutic benefit IFNg plays a significant role in the generation of antitumor responses (37, 38).”
BackgroundThe therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 64
Interferon α in cancer immunoediting: From elimination to escape
Vidal, P. D. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12863 · Cited by 69
Impact of proton therapy on antitumor immune response
Mirjolet, C., Nicol, A., Limagne, E., Mura, C., Richard, C., Morgand, V., Rousseau, M., Boidot, R., Ghiringhelli, F., Noël, G., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92942-1 · Cited by 62
Sisirak, V., Faget, J., Vey, N., Blay, J.-Y., Ménétrier-Caux, C., Caux, C., & Bendriss-Vermare, N. (2013) · OncoImmunology · doi:10.4161/onci.22338 · Cited by 60
Solodova, E., Jablonska, J., Weiss, S., & Lienenklaus, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018543 · Cited by 59
“For instance, they are involved in defense against many viruses [45–47], could be either protective or detrimental during non-viral pathogens [7,8], act in cancer surveillance [48,49], but they are also effector molecules in toxic shock elicited by LPS [50] and TNF [51].”
Potent Inhibition of Human Enterovirus 71 Replication by Type I Interferon Subtypes
Yi, L., He, Y., Chen, Y., Kung, H., & He, M. (2011) · Antiviral Therapy · doi:10.3851/imp1720 · Cited by 63
“Over the past two decades, type I IFNs have been successfully used to combat virus as well as a range of other diseases [31,32].”
BackgroundZhan, X., Guo, S., Li, Y., Ran, H., Huang, H., Mi, L., Wu, J., Wang, X., Xiao, D., Chen, L., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191340 · Cited by 62
“In the tumor microenvironment, type I IFNs are produced by immune cells, stromal cells, and even tumor cells and act in an autocrine or paracrine manner (Dunn et al., 2006; Parker et al., 2016; Zitvogel et al., 2015).”
BackgroundMa, Z., Li, Z., Mao, Y., Ye, J., Liu, Z., Wang, Y., Wei, C., Cui, J., Liu, Z., & Liang, X. (2023) · Nature Communications · doi:10.1038/s41467-023-41218-5 · Cited by 63
Skov, V., Larsen, T. S., Thomassen, M., Riley, C. H., Jensen, M. K., Bjerrum, O. W., Kruse, T. A., & Hasselbalch, H. C. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01618.x · Cited by 66
“During this evolution, the interferons are important cytokines for immunity and cancer immunoediting (59).”
BackgroundARF and p53 Coordinate Tumor Suppression of an Oncogenic IFN-β-STAT1-ISG15 Signaling Axis
Forys, J. T., Kuzmicki, C. E., Saporita, A. J., Winkeler, C. L., Maggi, L. B., & Weber, J. D. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.026 · Cited by 64
“In fact, type I IFN is an approved treatment for many diverse cancer types (Dunn et al., 2006).”
BackgroundMyeloid-derived suppressor cells: A novel therapeutic target
Ko, J. S., Bukowski, R. M., & Finke, J. H. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0014-6 · Cited by 66
“It has been shown in many ways, many different times, that a type 1 response is necessary for immune-mediated tumor rejection [11, 25 ].”
BackgroundLinks between innate and cognate tumor immunity
Ghiringhelli, F., Apétoh, L., Housseau, F., Kroemer, G., & Zitvogel, L. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.02.003 · Cited by 64
Brichard, V. G., & Lejeune, D. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.7.951 · Cited by 62
“Low-dose recombinant IFN- γ has been tested as adjuvant therapy in high-risk melanoma patients, but showed no clinical benefit in terms of disease-free interval (DFI) or overall survival [50,51] .”
MethodEmerging insights into head and neck cancer metastasis
Allen, C. T., Law, J. H., Dunn, G. P., & Uppaluri, R. (2012) · Head & Neck · doi:10.1002/hed.23202 · Cited by 61
“interaction with host immune system: equilibrium, elimination, or escape.(128) The presence of individual or groups”
BackgroundSelf-citationPost-Transcriptional Regulation of Interferons and Their Signaling Pathways
Savan, R. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2013.0117 · Cited by 63
Nuebling, T., Schumacher, C. E., Hofmann, M., Hagelstein, I., Schmiedel, B. J., Maurer, S., Federmann, B., Rothfelder, K., Roerden, M., Dörfel, D., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0212 · Cited by 63
The clinical implications of antitumor immunity in head and neck cancer
Allen, C. T., Judd, N. P., Bui, J. D., & Uppaluri, R. (2011) · The Laryngoscope · doi:10.1002/lary.21913 · Cited by 63
“and cellular components of adaptive immunity may mediate tumor elimination, equilibrium and eventual escape as part of the ‘‘immunoediting’’ hypothesis.(10,15,16)”
BackgroundInhibition of CSF-1R Supports T-Cell Mediated Melanoma Therapy
Sluijter, M., van der Sluis, T. C., van der Velden, P. A., Versluis, M., West, B. L., van der Burg, S. H., & van Hall, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104230 · Cited by 58
“The importance of INFc in the immune control of tumors is widely described [16] and reduced presence of macrophages in the local tumor environment is likely to empower effector functions of intratumoral T cells.”
BackgroundOncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
Fournier, P., & Schirrmacher, V. (2013) · Biology · doi:10.3390/biology2030936 · Cited by 72
Confounding roles for type I interferons during bacterial and viral pathogenesis
Carrero, J. A. (2013) · International Immunology · doi:10.1093/intimm/dxt050 · Cited by 68
“There is also extensive work on the role IFN-I in the pathogenesis of autoimmunity and cancer, and more recently, in fungal and protozoan infections (7) (8) (9) .”
BackgroundTeramoto, K., Igarashi, T., Kataoka, Y., Ishida, M., Hanaoka, J., Sumimoto, H., & Daigo, Y. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.013 · Cited by 59
Targeted therapy of cancer using diphtheria toxin-derived immunotoxins
Potala, S., Sahoo, S. K., & Verma, R. S. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.06.017 · Cited by 66
The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine
Li, X., Li, M., Huang, M., Lin, Q., Fang, Q., Liu, J., Chen, X., Liu, L., Zhan, X., Shan, H., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113064 · Cited by 63
Lesinski, G. B., Zimmerer, J. M., Kreiner, M., Trefry, J. C., Bill, M. A., Young, G. S., Becknell, B., & Carson, W. E. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-142 · Cited by 62
“Background Endogenously produced cytokines of the type I and type II interferon families are critical for the recognition of developing tumors by the immune system [1].”
BackgroundSignal transducers and activators of transcription—from cytokine signalling to cancer biology
Santos, C. I., & Costa‐Pereira, A. P. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.03.003 · Cited by 69
Riley, C. H., Hansen, M., Brimnes, M. K., Hasselbalch, H. C., Bjerrum, O. W., Straten, P. T., Svane, I. M., & Jensen, M. K. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12420 · Cited by 62
NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2
Xu, P., Ye, S., Li, K., Huang, M., Wang, Q., Zeng, S., Chen, X., Gao, W., Chen, J., Zhang, Q., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1448-9 · Cited by 62
Dendritic cells and cytokines in immune rejection of cancer
Ferrantini, M., Capone, I., & Belardelli, F. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.10.003 · Cited by 59
“In addition to the direct effects on tumor cells, considered for a long time the major mechanisms of the clinical response in IFN-treated patients [94], IFN-a exert several effects on host immune cells that can play a central role in the overall antitumor response and that have led to the recognition of the importance…”
BackgroundEnvironmental stimuli shape microglial plasticity in glioma
Garofalo, S., Porzia, A., Mainiero, F., Di Angelantonio, S., Cortese, B., Basilico, B., Pagani, F., Cignitti, G., Chece, G., Maggio, R., et al. (2017) · eLife · doi:10.7554/elife.33415 · Cited by 58
“Among the cytokines, interferon (IFN)-g contributes to tumor immune-surveillance and interacts with T cells, dendritic cells and monocytes (Kaplan et al., 1998; Dunn et al., 2006).”
Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia
Tomic, J., Lichty, B. D., & Spaner, D. (2011) · Blood · doi:10.1182/blood-2010-05-285999 · Cited by 60
Transcriptional changes induced by the tumor dormancy-associated microRNA-190
Almog, N., Briggs, C. E., Beheshti, A., Ma, L., Wilkie, K. P., Rietman, E. A., & Hlatky, L. (2013) · Transcription · doi:10.4161/trns.25558 · Cited by 58
Beaino, W., Nedrow, J. R., & Anderson, C. J. (2015) · Molecular Pharmaceutics · doi:10.1021/mp5006917 · Cited by 58
Wischhusen, J., Waschbisch, A., & Wiendl, H. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.07.005 · Cited by 62
Frick, L. R., Palumbo, M. L., Zappia, M. P., Brocco, M. A., Cremaschi, G., & Genaro, A. M. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.01.015 · Cited by 58
Chen, H., Fu, T., Suh, W., Tsavachidou, D., Wen, S., Gao, J., Tang, D. N., He, Q., Sun, J., & Sharma, P. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0155 · Cited by 61
Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations
Guo, S., Contratto, M., Miller, G., Leichman, L., & Wu, J. J. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i3.230 · Cited by 60
Schilling, B., Sondermann, W., Zhao, F., Griewank, K., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt587 · Cited by 58
“Since IFN-γ and IL-9 have been reported to play an important role in cancer immunosurveillance [20, 21], vemurafenib treatment of melanoma patients might have a dampening effect on anti-tumor immunity.”
BackgroundEgelston, C. A., Guo, W., Tan, J., Avalos, C., Simons, D. L., Lim, M. H., Huang, Y., Nelson, M. S., Chowdhury, A., Schmolze, D. B., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153963 · Cited by 60
“Our evidence therefore lends support to other findings of the potential protumorigenic role of IFN-γ signaling (53).”
ResultGarnier, L., Pick, R., Montorfani, J., Sun, M., Brighouse, D., Liaudet, N., Kammertoens, T., Blankenstein, T. J. F., Pagé, N., Bernier‐Latmani, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl5162 · Cited by 64
Albertus, D. L., Seder, C. W., Chen, G., Wang, X., Hartojo, W., Lin, L., Silvers, A. L., Thomas, D. G., Giordano, T. J., Chang, A. C., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318189f5ec · Cited by 60
Improving T cell responses to modified peptides in tumor vaccines
Buhrman, J. D., & Slansky, J. E. (2012) · Immunologic Research · doi:10.1007/s12026-012-8348-9 · Cited by 64
“Schreiber and colleagues collated evidence that encompasses the interaction between the immune system and cancer into a model called the three E’s of cancer immunoediting: elimination, equilibrium, and escape [12–14].”
Buechele, C., Baessler, T., Wirths, S., Schmohl, J. U., Schmiedel, B. J., & Salih, H. R. (2011) · Leukemia · doi:10.1038/leu.2011.313 · Cited by 57
The role of CD200 in immunity to B cell lymphoma
Wong, K. K. W., Khatri, I. A., Shaha, S., Spaner, D., & Gorczynski, R. M. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1009686 · Cited by 57
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
Mahmoud, F. A., Shields, B. D., Makhoul, I., Avaritt, N. L., Wong, H. K., Hutchins, L. F., Shalin, S. C., & Tackett, A. J. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1323596 · Cited by 60
“However, IFNg has been shown to enhance the MHC-I antigen processing and presentation pathway.(59) Buferne et al.”
BackgroundSpecifically differentiated T cell subset promotes tumor immunity over fatal immunity
Ramadan, A. M., Griesenauer, B., Adom, D., Kapur, R., Hanenberg, H., Liu, C., Kaplan, M. H., & Paczesny, S. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20170041 · Cited by 57
Contribution of Gut Microbiota to Colonic and Extracolonic Cancer Development
Compare, D., & Nardone, G. (2011) · Digestive Diseases · doi:10.1159/000332967 · Cited by 59
Combes, A. N., Spiller, C. M., Harley, V. R., Sinclair, A. H., Dunwoodie, S. L., Wilhelm, D., & Koopman, P. A. (2009) · The International Journal of Developmental Biology · doi:10.1387/ijdb.092920ac · Cited by 56
Chen, L., Yang, S., Liao, W., & Xiong, Y. (2015) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-015-0513-z · Cited by 58
“For example, IFN-c, Th1, and other cytokines have pivotal roles in promoting cancer immunoediting and antitumor immunity, especially for RCC immunotherapy [8, 9].”
Interferon γ-Induced Human Guanylate Binding Protein 1 Inhibits Mammary Tumor Growth in Mice
Lipnik, K., Naschberger, E., Britzen‐Laurent, N., Kodajova, P., Petznek, H., Rungaldier, S., Astigiano, S., Ferrini, S., Stürzl, M., & Hohenadl, C. (2010) · Molecular Medicine · doi:10.2119/molmed.2009.00172 · Cited by 55
Yan, J., Liu, X., Xiao, G., Li, N., Deng, Y.-N., Han, L., Yin, L.-C., Ling, L., & Liu, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096080 · Cited by 62
“Some studies have indicated that IFN-c was necessary for cytotoxic effector functions; moreover, it had anti-angiogenic effects in many tumor models [38].”
BackgroundThe antiviral effects of acteoside and the underlying IFN-γ-inducing action
Song, X., He, J., Xu, H. Y., Hu, X.-P., Wu, X.-L., Wu, H.-Q., Liu, L.-Z., Liao, C.-H., Zeng, Y., Li, Y., et al. (2016) · Food & Function · doi:10.1039/c6fo00335d · Cited by 59
Ahmed, S., Sulaiman, S. A., & Othman, N. H. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/5904361 · Cited by 55
Cancer-Immune Equilibrium: Questions Unanswered
Bhatia, A., & Kumar, Y. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0065-8 · Cited by 55
“Nevertheless, it has been suggested that CI equilibrium is solely maintained by adaptive immunity in contrast to the other two phases of cancer immunity which require elements from innate as well as adaptive immune response [15].”
BackgroundRakshit, S., Subramanian, B. C., Saha, B., Victor, E. S., Majumdar, S., & Nandi, D. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.06.014 · Cited by 59
Osteoimmunology in orthodontic tooth movement
Jiang, C., Li, Z., Quan, H., Li, X., Zhao, J., Jiang, C., Wang, Y., Liu, J., Gou, Y., An, S., et al. (2014) · Oral Diseases · doi:10.1111/odi.12273 · Cited by 60
Wimmers, F., Aarntzen, E. H. J. G., Boer, T. D., Figdor, C. G., Jacobs, J. F. M., Tel, J., & de Vries, I. J. M. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1067745 · Cited by 54
“such as TNFa, CCL4 and IFNg, were shown to play an important role as well.(1,13,14) Tumor cells treated with IFNg upregulate”
BackgroundFeng, L., Sheng, J., Vu, G.-P., Liu, Y., Foo, C., Wu, S., Trang, P., Paliza-Carre, M., Ran, Y., Yang, X., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006867 · Cited by 59
“Upon viral infection, IFN-γ [15, 16] activates cellular signaling networks, such as the JAK-STAT pathway [17, 18] .”
BackgroundGermain, C., Guillaudeux, T., Galsgaard, E. D., Hervouet, C., Tekaya, N., Gallouët, A.-S., Fassy, J., Bihl, F., Poupon, G., Lazzari, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1026503 · Cited by 55
Metadata
- Authors
- Dunn, G. P., Koebel, C. M., & Schreiber, R. D.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Schreiber, Robert D.
- Venue
- Nature Reviews Immunology
- Published
- 2006-11
- Volume
- 6
- Issue
- 11
- Pages
- 836-848
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2052313621
- Cited by
- 1,617
- References
- 119
- Citations by year
- 2026: 33 · 2025: 51 · 2024: 87 · 2023: 104 · 2022: 84 · 2021: 94 · 2020: 93 · 2019: 73 · 2018: 85 · 2017: 74 · 2016: 93 · 2015: 100 · 2014: 100 · 2013: 79 · 2012: 76
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- interferon, type I interferon, interferon-gamma, cancer immunoediting, tumor surveillance, antitumor immunity, tumor-immune interactions, interferon-alpha, interferon-beta, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunity, Immunotherapy, Interferons, Neoplasms, Monitoring, Immunologic, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.